

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α -2b in patients with resected high-risk melanoma

Journal: Cancer Chemotherapy and Pharmacology


A. I. Daud, C. Xu, W.-J. Hwu, P. Urbas, S. Andrews, N. E. Papadopoulos, L. C. Floren, A. Yver, R. C. DeConti, V. K. Sondak

Corresponding author: Adil Daud, MD, University of California San Francisco, San Francisco, CA 94143, USA; e-mail: adaud@medicine.ucsf.edu


ONLINE RESOURCE MATERIAL: SUPPLEMENTARY FIGURE 1

Goodness-of-fit plots **of one representative individual** for the absolute neutrophil count (ANC) pharmacokinetic/pharmacodynamic (PK/PD) model.


a Observed and predicted median ANC (percentage of baseline) vs time



b Weighted predicted vs observed median ANC (percentage of baseline)



c Weighted residual of predicted median ANC (percentage of baseline) vs weighted predicted median ANC (percentage of baseline): weighted residual vs Y



d Weighted residual of predicted median ANC (percentage of baseline) vs time (day): weighted residual vs X

